Michael J. Sofis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael J. Sofis has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Alan J. Budney
Center for Technology and Behavioral Health, Dartmouth Geisel School of Medicine
4 shared publications- Alan J. Budney
Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College, Lebanon, NH, United States
4 shared publications David P. Jarmolowicz
Cofrin Logan Center for Addiction Research and Treatment
3 shared publications- Jacob T. Borodovsky
Geisel School of Medicine at Dartmouth
3 shared publications Shea M. Lemley
Center for Technology and Behavioral Health
3 shared publications- Ari P. Kirshenbaum
Advocates for Human Potential Department of Innovation 490-B Boston Post Road Sudbury, Massachusetts, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Transplantation
- Vol. 2025 (1) , 4446435
Latent Profiles of Deceased Organ Donation Registrants and Nonregistrants in the United States
Deceased organ donation is the greatest source of transplantable whole organs, but registration rates are a limiting factor because they remain low among certain populations. A stratified, nonprobability survey was used to identify population characteristics associated with nonregistration in the United States ( N = 11,083). Latent profile analysis (LPA) was used to identify multivariate patterns of demographic, socioeconomic, and health‐related factors associated with registration. LPA yielded three distinct profiles, which all reported similar average percentages of driver’s license possession, medical insurance coverage, and income, indicating that profiles were not distinguished by these variables. Meaningful differences across the profiles included access to healthcare services, satisfaction with those services, general health and well‐being, and age; those who are both healthy and young (mean age = 25.9 years) reported the lowest percentage of organ donation registration (35.3%). For this group, 71.48% listed either low priority or distrust in the donation process as the top reasons for nonregistration. Importantly, age as a standalone variable was not uniformly associated with donation and was conditionally dependent upon health status; poorer health in young adults was associated with greater registration. These findings reveal previously unidentified opportunities for tailoring donor registration campaigns to populations with a high potential for registration behavior change.
- 1 January 2025
- Published by Wiley in Journal of Transplantation
- Vol. 2025 (1) , 4446435
Open AccessLatent Profiles of Deceased Organ Donation Registrants and Nonregistrants in the United States
Deceased organ donation is the greatest source of transplantable whole organs, but registration rates are a limiting factor because they remain low among certain populations. A stratified, nonprobability survey was used to identify population characteristics associated with nonregistration in the United States ( N = 11,083). Latent profile analysis (LPA) was used to identify multivariate patterns of demographic, socioeconomic, and health‐related factors associated with registration. LPA yielded three distinct profiles, which all reported similar average percentages of driver’s license possession, medical insurance coverage, and income, indicating that profiles were not distinguished by these variables. Meaningful differences across the profiles included access to healthcare services, satisfaction with those services, general health and well‐being, and age; those who are both healthy and young (mean age = 25.9 years) reported the lowest percentage of organ donation registration (35.3%). For this group, 71.48% listed either low priority or distrust in the donation process as the top reasons for nonregistration. Importantly, age as a standalone variable was not uniformly associated with donation and was conditionally dependent upon health status; poorer health in young adults was associated with greater registration. These findings reveal previously unidentified opportunities for tailoring donor registration campaigns to populations with a high potential for registration behavior change.
- Open Access
- 18 April 2024
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 19, 100545
Delay discounting is associated with addiction and mental health measures while controlling for health behaviors and health barriers in a large US sample
- 18 April 2024
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 19, 100545
Open AccessDelay discounting is associated with addiction and mental health measures while controlling for health behaviors and health barriers in a large US sample
- 1 December 2022
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 30 (6) , 918-927
Initial evaluation of domain-specific episodic future thinking on delay discounting and cannabis use.
Public Significance Statement Participation in a brief online intervention that prompts the creation and imagination of positive future events across life domains may help reduce frequent cannabis use. Episodic Future Thinking (EFT), mental simulation of personally relevant and positive future events, may modulate delay discounting (DD) in cannabis users. Whether EFT impacts cannabis use, whether DD mediates this effect, and whether EFT can be enhanced by prompting future events across specific life domains is unknown. Active, adult cannabis users (n = 90) recruited from Amazon mTurk and Qualtrics Panels were administered an Episodic Specificity Induction (ESI) to enhance quality of imagined events before being randomized to EFT, domain-specific-EFT (DS-EFT), or Episodic Recent Thinking (ERT). All participants created four, positive life events; DS-EFT participants imagined social, leisure, health, and financial events. Event-quality ratings were assessed (e.g., enjoyment). DD was assessed at baseline (Day 1), post-intervention (Days 2-4), and follow-up (Days 9-12). Cannabis use was assessed at baseline and follow-up. Differences in change in days and grams of cannabis use between conditions and mediation of changes in use by DD were examined. No differences in DD were observed between conditions. DS-EFT, but not EFT, showed significantly greater reductions in grams (d = .54) and days of cannabis use (d = .50) than ERT. DS-EFT and EFT demonstrated significantly greater event-quality ratings than ERT (ds > .55). EFT-based interventions showed potential for reducing cannabis use. Unexpectedly, effects on DD did not mediate this effect. Further testing with larger samples of cannabis users is needed to better understand EFT's mechanisms of action and determine optimal implementation strategies.
- 1 December 2022
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 30 (6) , 918-927
Initial evaluation of domain-specific episodic future thinking on delay discounting and cannabis use.
Public Significance Statement Participation in a brief online intervention that prompts the creation and imagination of positive future events across life domains may help reduce frequent cannabis use. Episodic Future Thinking (EFT), mental simulation of personally relevant and positive future events, may modulate delay discounting (DD) in cannabis users. Whether EFT impacts cannabis use, whether DD mediates this effect, and whether EFT can be enhanced by prompting future events across specific life domains is unknown. Active, adult cannabis users (n = 90) recruited from Amazon mTurk and Qualtrics Panels were administered an Episodic Specificity Induction (ESI) to enhance quality of imagined events before being randomized to EFT, domain-specific-EFT (DS-EFT), or Episodic Recent Thinking (ERT). All participants created four, positive life events; DS-EFT participants imagined social, leisure, health, and financial events. Event-quality ratings were assessed (e.g., enjoyment). DD was assessed at baseline (Day 1), post-intervention (Days 2-4), and follow-up (Days 9-12). Cannabis use was assessed at baseline and follow-up. Differences in change in days and grams of cannabis use between conditions and mediation of changes in use by DD were examined. No differences in DD were observed between conditions. DS-EFT, but not EFT, showed significantly greater reductions in grams (d = .54) and days of cannabis use (d = .50) than ERT. DS-EFT and EFT demonstrated significantly greater event-quality ratings than ERT (ds > .55). EFT-based interventions showed potential for reducing cannabis use. Unexpectedly, effects on DD did not mediate this effect. Further testing with larger samples of cannabis users is needed to better understand EFT's mechanisms of action and determine optimal implementation strategies.
- 1 August 2022
- Published by American Psychological Association (APA) in Psychology of Addictive Behaviors
- Vol. 36 (5) , 505-514
Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.
Abstinence is rarely achieved in clinical trials for cannabis use disorder (CUD). Cannabis reduction is associated with functional improvement, but reduction endpoints have not been established, indicating a need to identify and validate clinically meaningful reduction endpoints for assessing treatment efficacy. Data from a 12-week double-blind randomized placebo-controlled medication trial for cannabis cessation (NCT01675661) were analyzed. Participants (N = 225) were treatment-seeking adults, M = 30.6 (8.9) years old, 70.2% male, and 42.2% Non-White, with CUD who completed 12 weeks of treatment. Frequency (days of use per week) and quantity (grams per using day) were used to define high-, medium-, and low-risk levels. Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale and cannabis-related problems were assessed using the Marijuana Problems Scale. General linear models for repeated measures tested associations between the magnitude of risk reduction and functional outcomes from baseline (BL) to end-of-treatment (EOT). Cannabis risk levels were sensitive to reductions in use from BL to EOT for frequency- (χ² = 19.35, p = .004) and quantity-based (χ² = 52.06, p < .001) metrics. Magnitude reduction in frequency-based risk level was associated with magnitude decrease in depression (F = 2.76, p = .043, ηp² = .04), anxiety (F = 3.70, p = .013, ηp² = .05), and cannabis-related problems (F = 8.95, p < .001, ηp² = .12). Magnitude reduction in quantity-based risk level was associated with magnitude decrease in anxiety (F = 3.02, p = .031, ηp² = .04) and cannabis-related problems (F = 3.24, p = .023, ηp² = .05). Cannabis use risk levels, as operationalized in this study, captured reductions in use during a clinical trial. Risk level reduction was associated with functional improvement suggesting that identifying risk levels and measuring the change in levels over time may be a viable and clinically meaningful endpoint for determining treatment efficacy. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
- 1 August 2022
- Published by American Psychological Association (APA) in Psychology of Addictive Behaviors
- Vol. 36 (5) , 505-514
Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.
Abstinence is rarely achieved in clinical trials for cannabis use disorder (CUD). Cannabis reduction is associated with functional improvement, but reduction endpoints have not been established, indicating a need to identify and validate clinically meaningful reduction endpoints for assessing treatment efficacy. Data from a 12-week double-blind randomized placebo-controlled medication trial for cannabis cessation (NCT01675661) were analyzed. Participants (N = 225) were treatment-seeking adults, M = 30.6 (8.9) years old, 70.2% male, and 42.2% Non-White, with CUD who completed 12 weeks of treatment. Frequency (days of use per week) and quantity (grams per using day) were used to define high-, medium-, and low-risk levels. Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale and cannabis-related problems were assessed using the Marijuana Problems Scale. General linear models for repeated measures tested associations between the magnitude of risk reduction and functional outcomes from baseline (BL) to end-of-treatment (EOT). Cannabis risk levels were sensitive to reductions in use from BL to EOT for frequency- (χ² = 19.35, p = .004) and quantity-based (χ² = 52.06, p < .001) metrics. Magnitude reduction in frequency-based risk level was associated with magnitude decrease in depression (F = 2.76, p = .043, ηp² = .04), anxiety (F = 3.70, p = .013, ηp² = .05), and cannabis-related problems (F = 8.95, p < .001, ηp² = .12). Magnitude reduction in quantity-based risk level was associated with magnitude decrease in anxiety (F = 3.02, p = .031, ηp² = .04) and cannabis-related problems (F = 3.24, p = .023, ηp² = .05). Cannabis use risk levels, as operationalized in this study, captured reductions in use during a clinical trial. Risk level reduction was associated with functional improvement suggesting that identifying risk levels and measuring the change in levels over time may be a viable and clinically meaningful endpoint for determining treatment efficacy. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
- 1 October 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 227, 108939
Correlates of continued cannabis use during pregnancy
- 1 October 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 227, 108939
Correlates of continued cannabis use during pregnancy
- 1 February 2021
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 29 (1) , 99-115
The importance of psychology for shaping legal cannabis regulation.
Different patterns of cannabis use can be traced directly back to different interactions between 2 types of variables: pharmacological and environmental. As legal cannabis expands in the U.S. and around the world, state and national regulatory agencies are gaining control over these variables. Specifically, regulatory agencies are increasingly capable of altering (a) the pharmacological properties of cannabis products and (b) the way these products are distributed to the population. Consequently, cannabis regulatory agencies are in a unique position to use evidence from psychological science to alter cannabis consumption patterns in ways that mitigate potential harm to public health. However, most state-level legal cannabis regulatory systems in the U.S. are not yet evidence-based or public health-oriented. This applied review and commentary draws on evidence from the psychological science literature to help regulators better understand the types of behaviors they must address and guide empirically supported regulation of THC-laden cannabis, whether used putatively for medical or recreational reasons. This review is organized into 3 parts that correspond to the 3 primary agents within the cannabis regulation ecosystem: (a) the cannabis consumer, (b) the cannabis industry, and (c) the cannabis regulatory agency. Within this structure, the review addresses critical psychological variables that drive cannabis consumer and industry behaviors and discusses how regulatory agencies can use this information to protect public health. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
- 1 February 2021
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 29 (1) , 99-115
The importance of psychology for shaping legal cannabis regulation.
Different patterns of cannabis use can be traced directly back to different interactions between 2 types of variables: pharmacological and environmental. As legal cannabis expands in the U.S. and around the world, state and national regulatory agencies are gaining control over these variables. Specifically, regulatory agencies are increasingly capable of altering (a) the pharmacological properties of cannabis products and (b) the way these products are distributed to the population. Consequently, cannabis regulatory agencies are in a unique position to use evidence from psychological science to alter cannabis consumption patterns in ways that mitigate potential harm to public health. However, most state-level legal cannabis regulatory systems in the U.S. are not yet evidence-based or public health-oriented. This applied review and commentary draws on evidence from the psychological science literature to help regulators better understand the types of behaviors they must address and guide empirically supported regulation of THC-laden cannabis, whether used putatively for medical or recreational reasons. This review is organized into 3 parts that correspond to the 3 primary agents within the cannabis regulation ecosystem: (a) the cannabis consumer, (b) the cannabis industry, and (c) the cannabis regulatory agency. Within this structure, the review addresses critical psychological variables that drive cannabis consumer and industry behaviors and discusses how regulatory agencies can use this information to protect public health. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
- 24 July 2020
- Published by Elsevier in Addictive Behaviors
- Vol. 112, 106573
Sifting through the weeds: Relationships between cannabis use frequency measures and delay discounting
- 24 July 2020
- Published by Elsevier in Addictive Behaviors
- Vol. 112, 106573
Sifting through the weeds: Relationships between cannabis use frequency measures and delay discounting
- 1 June 2020
- Published by American Psychological Association (APA) in Psychology of Addictive Behaviors
- Vol. 34 (4) , 532-540
A web-based episodic specificity and future thinking session modulates delay discounting in cannabis users.
Episodic future thinking (EFT), a brief intervention involving mental simulation of positive future events, improves delay discounting (DD) in nicotine and alcohol dependent individuals. This study is the first to assess effects of a single-session, online episodic training (ET) on constructs that might impact cannabis use and cannabis use disorder. A sample of 200 active cannabis users recruited via Amazon Mechanical Turk were randomized to an EFT group (n = 102) or an episodic recent thinking control group (ERT; n = 98). A novel episodic specificity induction (ES) was included to enhance quality of episodic thinking for the ET group, and an ES attention control was provided to the ERT group (control training group; CT). Quality and manipulation ratings of event excitement, vividness, importance, and enjoyment of trainings were collected in addition to DD tasks (gains and losses) and readiness to change cannabis use. The ET group reported higher overall quality and manipulation ratings than did the CT group (p < .001, d = 0.79). DD of gains was lower in the ET relative to those of the CT group after controlling for relevant variables (p = .003, d = 0.48), unlike DD of losses (p = .50, d = 0.11). The ET group showed larger pre/post increases in readiness to change, but they were not statistically significant (p = .069, d = 0.26). These effects, following a session of online ET, suggests that ET may positively impact factors related to reduction in cannabis use. Differential effects of EFT and ES components on DD and the development of ET as an adjunctive mHealth intervention targeting reduction in cannabis use appears warranted. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
- 1 June 2020
- Published by American Psychological Association (APA) in Psychology of Addictive Behaviors
- Vol. 34 (4) , 532-540
A web-based episodic specificity and future thinking session modulates delay discounting in cannabis users.
Episodic future thinking (EFT), a brief intervention involving mental simulation of positive future events, improves delay discounting (DD) in nicotine and alcohol dependent individuals. This study is the first to assess effects of a single-session, online episodic training (ET) on constructs that might impact cannabis use and cannabis use disorder. A sample of 200 active cannabis users recruited via Amazon Mechanical Turk were randomized to an EFT group (n = 102) or an episodic recent thinking control group (ERT; n = 98). A novel episodic specificity induction (ES) was included to enhance quality of episodic thinking for the ET group, and an ES attention control was provided to the ERT group (control training group; CT). Quality and manipulation ratings of event excitement, vividness, importance, and enjoyment of trainings were collected in addition to DD tasks (gains and losses) and readiness to change cannabis use. The ET group reported higher overall quality and manipulation ratings than did the CT group (p < .001, d = 0.79). DD of gains was lower in the ET relative to those of the CT group after controlling for relevant variables (p = .003, d = 0.48), unlike DD of losses (p = .50, d = 0.11). The ET group showed larger pre/post increases in readiness to change, but they were not statistically significant (p = .069, d = 0.26). These effects, following a session of online ET, suggests that ET may positively impact factors related to reduction in cannabis use. Differential effects of EFT and ES components on DD and the development of ET as an adjunctive mHealth intervention targeting reduction in cannabis use appears warranted. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
- 1 April 2020
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 28 (2) , 225-234
Persisting on the past: Cross-sectional and prospective associations between sunk cost propensity and cannabis use.
Prevalence of cannabis use in the United States continues to rise, and 30% of cannabis users eventually meet criteria for Cannabis Use Disorder (CUD). One response to this problem is to develop decision-making constructs that indicate vulnerability to CUD that might not be gleaned from diagnostic criteria. Unfortunately, there is limited evidence that decision-making constructs consistently relate to cannabis use. Interestingly, those who exhibit the sunk cost bias, an overgeneralized tendency to persist based on past investment, and those who use cannabis, both tend to focus on the past and perseverate more than their counterparts. Despite this overlap, no studies have assessed whether the sunk cost bias is positively associated with cannabis use. In 2 experiments with undergraduates, relations between cannabis use and the propensity to engage in the sunk cost bias were examined using negative binomial models. Experiment 1 (n = 46) evaluated the association between sunk cost bias propensity (using hypothetical costs and rewards) and frequency of cannabis use over the past 30 days. Greater sunk cost propensity was associated with more frequent cannabis use after controlling for demographics and alcohol use. In Experiment 2 (n = 103), more frequent cannabis use during a 6-week follow-up period was predicted by greater sunk cost propensity at baseline (using a real cost and reward-based task), independently and after controlling for mental health symptoms, alcohol use, and demographics. These findings provide preliminary evidence that a propensity to exhibit the sunk cost bias may be an important feature associated with cannabis use.
- 1 April 2020
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 28 (2) , 225-234
Persisting on the past: Cross-sectional and prospective associations between sunk cost propensity and cannabis use.
Prevalence of cannabis use in the United States continues to rise, and 30% of cannabis users eventually meet criteria for Cannabis Use Disorder (CUD). One response to this problem is to develop decision-making constructs that indicate vulnerability to CUD that might not be gleaned from diagnostic criteria. Unfortunately, there is limited evidence that decision-making constructs consistently relate to cannabis use. Interestingly, those who exhibit the sunk cost bias, an overgeneralized tendency to persist based on past investment, and those who use cannabis, both tend to focus on the past and perseverate more than their counterparts. Despite this overlap, no studies have assessed whether the sunk cost bias is positively associated with cannabis use. In 2 experiments with undergraduates, relations between cannabis use and the propensity to engage in the sunk cost bias were examined using negative binomial models. Experiment 1 (n = 46) evaluated the association between sunk cost bias propensity (using hypothetical costs and rewards) and frequency of cannabis use over the past 30 days. Greater sunk cost propensity was associated with more frequent cannabis use after controlling for demographics and alcohol use. In Experiment 2 (n = 103), more frequent cannabis use during a 6-week follow-up period was predicted by greater sunk cost propensity at baseline (using a real cost and reward-based task), independently and after controlling for mental health symptoms, alcohol use, and demographics. These findings provide preliminary evidence that a propensity to exhibit the sunk cost bias may be an important feature associated with cannabis use.